Because ovarian cancer uniquely presents at a more advanced stage relative to other cancers (18), we ran a sensitivity analysis that excluded the cases of ovarian cancer; enrichment of low-stage cancers in the anti-CCAR1–positive group remained significant (P = 0.05, Fischer’s exact test). This evidence concerns the gene CCAR1 and ovarian carcinoma.